Il y a eu 50 transactions d'initiés récentes enregistrées pour CymaBay Therapeutics, Inc. (CBAY), dont 11 achats et 39 ventes. Le total des achats d'initiés s'élève à $1.92M et le total des ventes d'initiés à $21.25M.
Les initiés notables ayant une activité récente comprennent Wiggans Thomas G, Emster Kurt Von, Quinlan Paul T. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — CBAY
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2024-03-22 |
Wiggans Thomas G |
Director |
Restitution d'Actions |
14,010 |
$22.85 |
$320.13K |
- |
| 2024-03-22 |
Emster Kurt Von |
Director |
Restitution d'Actions |
14,010 |
$22.85 |
$320.13K |
- |
| 2024-03-22 |
Quinlan Paul T |
General Counsel |
Restitution d'Actions |
105,625 |
$22.85 |
$2.41M |
- |
| 2024-03-22 |
Dickinson Klara |
Chief Regulatory Officer |
Restitution d'Actions |
78,000 |
$22.85 |
$1.78M |
- |
| 2024-03-22 |
Loewy Caroline M |
Director |
Restitution d'Actions |
14,010 |
$22.85 |
$320.13K |
- |
| 2024-03-22 |
Shah Sujal |
Chief Executive Officer |
Restitution d'Actions |
357,500 |
$22.85 |
$8.17M |
- |
| 2024-03-22 |
Mcwherter Charles |
President of R&d |
Restitution d'Actions |
118,625 |
$22.85 |
$2.71M |
- |
| 2024-03-22 |
Lefebvre Eric |
Director |
Restitution d'Actions |
14,010 |
$22.85 |
$320.13K |
- |
| 2024-03-22 |
Wills Robert James |
Director |
Restitution d'Actions |
14,010 |
$22.85 |
$320.13K |
- |
| 2024-03-22 |
Dorling Janet |
Director |
Restitution d'Actions |
14,010 |
$22.85 |
$320.13K |
- |
| 2024-03-22 |
Shantharam Harish |
Chief Financial Officer |
Restitution d'Actions |
74,750 |
$22.85 |
$1.71M |
- |
| 2024-03-13 |
Quinlan Paul T |
General Counsel |
Exercice d'Options (Vente) |
41,824 |
$7.89 |
$329.99K |
8,872 |
| 2024-03-13 |
Shah Sujal |
Chief Executive Officer |
Exercice d'Options (Vente) |
14,625 |
$1.06 |
$15.5K |
- |
| 2024-02-12 |
Dorling Janet |
Director |
Vente Informative |
6,000 |
$31.97 |
$191.85K |
- |
| 2024-01-24 |
Wiggans Thomas G |
Director |
Attribution de RSU |
14,010 |
$22.85 |
$320.13K |
14,010 |
| 2024-01-24 |
Emster Kurt Von |
Director |
Attribution de RSU |
14,010 |
$22.85 |
$320.13K |
14,010 |
| 2024-01-24 |
Quinlan Paul T |
General Counsel |
Attribution de RSU |
28,438 |
- |
- |
28,438 |
| 2024-01-24 |
Dickinson Klara |
Chief Regulatory Officer |
Attribution de RSU |
21,000 |
- |
- |
21,000 |
| 2024-01-24 |
Loewy Caroline M |
Director |
Attribution de RSU |
14,010 |
$22.85 |
$320.13K |
14,010 |
| 2024-01-24 |
Shah Sujal |
Chief Executive Officer |
Attribution de RSU |
96,250 |
- |
- |
267,551 |
| 2024-01-24 |
Mcwherter Charles |
President of R&d |
Attribution de RSU |
31,938 |
- |
- |
46,938 |
| 2024-01-24 |
Lefebvre Eric |
Director |
Attribution de RSU |
14,010 |
$22.85 |
$320.13K |
14,010 |
| 2024-01-24 |
Wills Robert James |
Director |
Attribution de RSU |
14,010 |
$22.85 |
$320.13K |
14,010 |
| 2024-01-24 |
Dorling Janet |
Director |
Attribution de RSU |
14,010 |
$22.85 |
$320.13K |
14,010 |
| 2024-01-24 |
Shantharam Harish |
Chief Financial Officer |
Attribution de RSU |
20,125 |
- |
- |
20,125 |
| 2024-01-19 |
Mcwherter Charles |
President of R&d |
Vente Informative |
2,250 |
$23.67 |
$53.26K |
15,000 |
| 2024-01-16 |
Quinlan Paul T |
General Counsel |
Vente Informative |
5,000 |
$23.58 |
$117.9K |
- |
| 2024-01-16 |
Menold Daniel |
Vice President, Finance |
Vente Informative |
10,000 |
$23.58 |
$235.81K |
- |
| 2024-01-10 |
Dorling Janet |
Director |
Vente Informative |
6,000 |
$23.86 |
$143.14K |
- |
| 2023-12-18 |
Mcwherter Charles |
President of R&d |
Exercice d'Options (Vente) |
6,504 |
$5.00 |
$32.52K |
- |
| 2023-12-15 |
Quinlan Paul T |
General Counsel |
Vente Informative |
5,000 |
$21.98 |
$109.9K |
- |
| 2023-12-15 |
Menold Daniel |
Vice President, Finance |
Vente Informative |
10,000 |
$21.98 |
$219.85K |
- |
| 2023-12-11 |
Shah Sujal |
Chief Executive Officer |
Exercice d'Options (Vente) |
12,973 |
$5.00 |
$64.87K |
- |
| 2023-12-11 |
Dorling Janet |
Director |
Vente Informative |
6,000 |
$20.07 |
$120.42K |
- |
| 2023-11-17 |
Mcwherter Charles |
President of R&d |
Exercice d'Options (Vente) |
236 |
$5.00 |
$1.18K |
234 |
| 2023-11-15 |
Quinlan Paul T |
General Counsel |
Vente Informative |
5,000 |
$17.38 |
$86.89K |
- |
| 2023-11-15 |
Menold Daniel |
Vice President, Finance |
Vente Informative |
- |
$17.38 |
- |
- |
| 2023-11-13 |
Shah Sujal |
Chief Executive Officer |
Exercice d'Options (Vente) |
12,972 |
$5.00 |
$64.86K |
12,973 |
| 2023-11-10 |
Dorling Janet |
Director |
Vente Informative |
7,000 |
$15.24 |
$106.7K |
- |
| 2023-10-18 |
Mcwherter Charles |
President of R&d |
Exercice d'Options (Vente) |
10,401 |
$5.00 |
$52.01K |
- |
| 2023-10-16 |
Quinlan Paul T |
General Counsel |
Vente Informative |
5,000 |
$13.76 |
$68.8K |
- |
| 2023-10-16 |
Menold Daniel |
Vice President, Finance |
Vente Informative |
- |
$13.76 |
- |
- |
| 2023-10-09 |
Shah Sujal |
Chief Executive Officer |
Exercice d'Options (Vente) |
12,972 |
$5.00 |
$64.86K |
25,945 |
| 2023-09-29 |
Emster Kurt Von |
Director |
Exercice d'Options (Vente) |
5,249 |
$5.00 |
$26.25K |
- |
| 2023-09-18 |
Mcwherter Charles |
President of R&d |
Exercice d'Options (Vente) |
236 |
$5.00 |
$1.18K |
706 |
| 2023-09-15 |
Quinlan Paul T |
General Counsel |
Vente Informative |
24,000 |
$16.87 |
$404.92K |
- |
| 2023-09-15 |
Menold Daniel |
Vice President, Finance |
Exercice d'Options (Vente) |
15,000 |
$1.72 |
$25.8K |
- |
| 2023-09-13 |
Avoro Capital Advisors Llc |
10 Percent Owner |
Vente Informative |
250 |
$17.00 |
$4.25K |
250 |
| 2023-09-12 |
Avoro Capital Advisors Llc |
10 Percent Owner |
Vente Informative |
300 |
$17.00 |
$5.1K |
300 |
| 2023-08-18 |
Mcwherter Charles |
President of R&d |
Exercice d'Options (Vente) |
236 |
$5.00 |
$1.18K |
942 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
